The government is supporting the investment, which will create 104 jobs, with a HUF 1.8 bln grant. 

The plantʼs warehouse capacity will be expanded and a new unit producing pharmaceutical raw materials will be built, as a result of which the plantʼs output will triple, the minister said.

Christopher Hunley, managing director of GSK Biologicals, said the activity of the unit will be expanded as a result of the development and the plant will make components of diphtheria and tetanus vaccines for a new area of utilization.